Immix Biopharma, Inc. (IMMX) – What Are Brokerages Saying About This Stock?

Shares of Immix Biopharma, Inc. (NASDAQ:IMMX) have received a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and eight have given a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $23.86.

IMMX has been the topic of several analyst reports. Morgan Stanley reiterated an “overweight” rating on shares of Immix Biopharma in a report on Tuesday, October 20th. Needham & Company LLC raised their price target on Immix Biopharma from $21.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, September 29th. HC Wainwright boosted their price target on Immix Biopharma from $20.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Mizuho set a $23.00 price objective on Immix Biopharma in a research note on Thursday, October 29th. Finally, Citigroup reissued a “market outperform” rating on shares of Immix Biopharma in a report on Wednesday, September 30th.

Immix Biopharma Price Performance

NASDAQ:IMMX traded down $0.23 on Friday, hitting $7.84. 1,027,813 shares of the company’s stock were exchanged, compared to its average volume of 1,218,249. The firm has a 50-day moving average price of $9.82 and a 200-day moving average price of $9.58. Immix Biopharma has a 52 week low of $3.56 and a 52 week high of $15.10. The company has a market cap of $560.87 million, a P/E ratio of -9.45 and a beta of 0.29.

Immix Biopharma (NASDAQ:IMMX) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.19) EPS for the quarter, hitting analysts’ consensus estimates of ($0.19). On average, research analysts expect that Immix Biopharma will post -0.76 earnings per share for the current fiscal year.

Institutional Trading of Immix Biopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in IMMX. Jupiter Topco LLC bought a new stake in shares of Immix Biopharma in the 2nd quarter valued at about $100,816,000. BlackRock Inc. bought a new position in Immix Biopharma during the second quarter worth about $30,827,000. Opaleye Management Inc. bought a new position in Immix Biopharma during the second quarter worth about $24,177,000. Wellington Management Group LLP acquired a new position in Immix Biopharma during the second quarter worth approximately $15,191,000. Finally, Janus Henderson Group PLC increased its position in Immix Biopharma by 22.5% during the first quarter. Janus Henderson Group PLC now owns 4,802,002 shares of the company’s stock worth $43,698,000 after buying an additional 880,434 shares during the last quarter. 11.26% of the stock is owned by institutional investors.

Immix Biopharma Company Profile

Immix Biopharma is a clinical-stage biopharmaceutical company developing cell therapies for serious diseases, with a focus on relapsed or refractory AL amyloidosis, a rare condition in which abnormal proteins build up in organs and tissues. The company’s lead candidate, NXC-201, is an investigational CAR T-cell therapy designed to target BCMA, a protein found on certain plasma cells. It is being studied in clinical trials and has not been approved for commercial use. Immix Biopharma is based in the United States and is led by Chief Executive Officer Ilya Rachman.